ASSESSMENT OF INTERACTION OF COCAINE AND QUETIAPINE (SEROQUEL)

可卡因和喹硫平（思瑞康）相互作用的评估

• 批准号: 7379484
• 负责人: DOMENIC A CIRAULO
• 金额: $ 6.41万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379484
• 关键词: ASSESSMENT; INTERACTION; COCAINE; QUETIAPINE; SEROQUEL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Study Objectives: This is a human laboratory clinical pharmacology study to assess the safety of intravenous cocaine in subjects taking quetiapine at 3 dosage levels. The purpose is to provide preliminary subjective, safety, and tolerability data to inform a decision on whether clinical trials of quetiapine in cocaine dependence should be conducted. Primary: the primary objective is to determine whether there are significant interactions between quetiapine administered concurrently with IV cocaine infusions of 20 mg and 40 mg by measuring subjective, laboratory, and physiologic responses. Secondary: 1. To evaluate whether the administration of quetiapine alters the pharmacokinetics of cocaine or its major metabolite, benzoylecgonine (BE). 2. To evaluate whether treatment with quetiapine alters the effects of cocaine on craving, as measured by subjective rating scales that assess abuse liability, for the purpose of determining whether there is a signal for potential efficacy in cocaine dependence. 3. To assess the effect of quetiapine on mood and personality using standard assessment scales.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。研究目标：这是一项人体实验室临床药理学研究，旨在评估静脉注射可卡因在接受3个剂量水平奎替鲁的受试者中的安全性。目的是提供初步的主观、安全性和耐受性数据，以决定是否应进行奎替鲁治疗可卡因依赖的临床试验。 初级：主要目的是通过测量主观的、实验室的和生理的反应来确定与20 mg和40 mg可卡因静脉输注同时给药的奎替利之间是否存在显著的相互作用。 中学：1.评价奎替利汀给药是否改变可卡因或其主要代谢物苯甲酰爱子碱（BE）的药代动力学。2.通过评估滥用倾向的主观评定量表，评价奎替卡松治疗是否改变可卡因对渴望的影响，以确定是否存在可卡因依赖的潜在疗效信号。3.使用标准评估量表评估奎替卡松对情绪和人格的影响。